Investigational drug · Phase 2
Ifetroban
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "Ifetroban"
First trial start
2017
Jan 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ifetroban", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Scleroderma, Diffuse
- Scleroderma, Systemic
- Scleroderma, Limited
- Sclerosis, Progressive Systemic
- Skin Diseases
- Connective Tissue Diseases
- Pathologic Processes
- Autoimmune Diseases
- Idiopathic Pulmonary Fibrosis
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ifetroban" as an intervention, largest first.
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
Cumberland PharmaceuticalsIndustry
NCT05571059 · 128 participants (planned) · Start Jan 31, 2024 · Primary completion Jan 2028
Drug: Ifetroban Sodium; Placebo · For: Idiopathic Pulmonary Fibrosis
Sites: La Mesa, California; San Francisco, California; Farmington, Connecticut · 20 sites in all
Jeffrey RadeAcademic, hospital or other
NCT03962855 · 57 participants · Start Sep 20, 2019 · Primary completion Nov 7, 2022
Drug: Ifetroban Sodium; Placebo · For: Cardiovascular Diseases; Vascular Dilation
Sites: Worcester, Massachusetts
Cumberland PharmaceuticalsIndustry
NCT01436500 · 55 participants · Start Oct 2011 · Primary completion Jun 2015
Drug: Ifetroban Injection; Placebo · For: Hepatorenal Syndrome
Sites: Phoenix, Arizona; La Jolla, California; San Francisco, California · 12 sites in all
Cumberland PharmaceuticalsIndustry
NCT03028350 · 54 participants · Start Jul 17, 2017 · Primary completion Apr 25, 2023
Drug: Ifetroban Oral Capsule; Placebo Oral Capsule · For: Asthma, Aspirin-Induced
Sites: Tucson, Arizona; Lancaster, California; San Diego, California · 16 sites in all
Cumberland PharmaceuticalsIndustry
NCT03340675 · 46 participants · Start Oct 19, 2020 · Primary completion Mar 6, 2024
Drug: Ifetroban; Placebo · For: Duchenne Muscular Dystrophy Cardiomyopathy; Cardiomyopathy, Dilated
Sites: Little Rock, Arkansas; Los Angeles, California; Washington D.C., District of Columbia · 10 sites in all
Brigham and Women's HospitalAcademic, hospital or other
NCT03326063 · 38 participants · Start Apr 26, 2018 · Primary completion Mar 30, 2022
Drug: Ifetroban; Placebo · For: Nasal Polyps; Asthma, Aspirin-Induced; Aspirin-exacerbated Respiratory Disease and 1 more
Sites: Boston, Massachusetts
- Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial HypertensionActive, not recruiting
Cumberland PharmaceuticalsIndustry
NCT02682511 · 34 participants (planned) · Start Jan 2017 · Primary completion Mar 2026
Drug: Oral Ifetroban; Oral Placebo · For: Scleroderma, Diffuse; Scleroderma, Systemic; Scleroderma, Limited and 5 more
Sites: Tucson, Arizona; Los Angeles, California; Weston, Florida · 13 sites in all
Cumberland PharmaceuticalsIndustry
NCT02802228 · 30 participants · Start Mar 6, 2017 · Primary completion Jul 17, 2018
Drug: Ifetroban; Placebo · For: Portal Hypertension; Liver Cirrhosis
Sites: Tampa, Florida; Indianapolis, Indiana; Columbus, Ohio · 6 sites in all
- Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic RecurrenceStatus unknown
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT03694249 · 30 participants · Start Dec 12, 2018 · Primary completion Apr 2025
Drug: Ifetroban Sodium · For: Malignant Solid Tumor
Sites: Nashville, Tennessee
Cumberland PharmaceuticalsIndustry
NCT02216357 · 19 participants · Start Aug 2014 · Primary completion Jan 2016
Drug: Ifetroban, Oral Capsule; Placebo, Oral Capsule · For: Aspirin Exacerbated Respiratory Disease (AERD)
Sites: San Diego, California; Overland Park, Kansas; West Nyack, New York
Newest research
PubMed records naming it or its code names, newest first.
- Targeting platelet-tumor cell interactions via thromboxane A2-prostanoid receptor blockade to reduce metastasis in triple negative breast cancer.
Toragall V, Rester AC, Begum S, et al. · Exp Hematol Oncol 2025
- Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update.
Lupu M, Pintilie IM, Teleanu RI, et al. · Int J Mol Sci 2025
- Correction Notice: Microscopy and Plate Reader-based Methods for Monitoring the Interaction of Platelets and Tumor Cells in vitro.
Toragall V, Hale EJ, Hulugalla KR, et al. · Bio Protoc 2023
- Trial of thromboxane receptor inhibition with ifetroban: TP receptors regulate eicosanoid homeostasis in aspirin-exacerbated respiratory disease.
Laidlaw TM, Buchheit KM, Cahill KN, et al. · J Allergy Clin Immunol 2023
- Perspectives on the advances in the pharmacotherapeutic management of Duchenne muscular dystrophy.
Kracht KD, Eichorn NL, Berlau DJ · Expert Opin Pharmacother 2022
- Thromboxane-Prostanoid Receptor Signaling Drives Persistent Fibroblast Activation in Pulmonary Fibrosis.
Suzuki T, Kropski JA, Chen J, et al. · Am J Respir Crit Care Med 2022
Also in development for Scleroderma, Diffuse
- rapcabtagene autoleucelYTB323Phase 28 trials
Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.